CD274 and cancer: Even though immunotherapies targeting classical checkpoints such as CTLA-4, PD-1, or PD-L1 have made substantial progress in different types of cancer, a large number of patients remain unresponsive to treatment, suggesting a vacancy for potential mechanisms of inhibitory ligand-receptor pathways (1).